- Home
- BYFC vs EQ Comparison
BYFC vs EQ Comparison
Compare BYFC & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BYFC | EQ |
|---|---|---|
| Founded | 1946 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.3M | 89.4M |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BYFC | EQ |
|---|---|---|
| Price | $11.66 | $1.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.56 |
| AVG Volume (30 Days) | 1.7K | ★ 543.3K |
| Earning Date | 07-28-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | $184,000.00 | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $162.43 | ★ N/A |
| Revenue Growth | ★ 18.71 | N/A |
| 52 Week Low | $5.51 | $1.19 |
| 52 Week High | $12.35 | $6.20 |
Technical Indicators
Market Signals| Indicator | BYFC | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 39.55 | 25.58 |
| Support Level | $9.29 | N/A |
| Resistance Level | $12.27 | $1.51 |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout BYFC Broadway Financial Corporation
Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank offers a variety of commercial real estate loan products, services, and depository accounts that support investments in affordable housing, small businesses, and nonprofit community facilities located within low-to-moderate income neighborhoods.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.